06/11/2017. COPD What s new? Learning outcomes. COPD why is the correct diagnosis important?
|
|
- Eleanore Washington
- 5 years ago
- Views:
Transcription
1 COPD What s new? Learning outcomes Professor Peter R Bremner University of Notre Dame St John of God Murdoch Current issues in management of COPD Identification of COPD Initiation of treatment COPD exacerbations Non-pharmacological interventions Device selection WHAT ARE THE CURRENT ISSUES IN COPD MANAGEMENT? ACCURATE COPD DIAGNOSIS IS OFTEN LATE DIAGNOSIS Delayed diagnosis, misdiagnosis, underuse of spirometry 1-4 UNDERUSE OF PULMONARY REHABILITATION INAPPROPRIATE USE OF INHALED CORTICOSTEROIDS 6 COPD IS UNDERDIAGNOSED 50% of all symptomatic COPD remains undiagnosed 1 WHY? Signs and symptoms may be subtle 2 Attributed to ageing or other conditions 3 Underuse of spirometry as a diagnostic tool 4 COPD IS OFTEN MISDIAGNOSED 5 Commonly misdiagnosed as asthma, and vice versa 6,7 Delayed use of appropriate interventions for COPD Remember to take into consideration comorbid conditions such as ischaemic heart disease, osteoporosis, metabolic syndrome, lung cancer, mental health etc, which significantly impact on prognosis References: 1. Lung Foundation Australia. Position paper on the use of COPD screening devices for targeted COPD case finding in community settings.lungfoundation.com.au. 2. Lung Foundation Australia. COPD: The statistics. lungfoundation.com.au. 3. Walters JA et al. Prim Care Respir J 2011; 20: Soriano JB et al. Lancet 2009; 374: Johnston K, Grimmer-Somers K. Physiother Can 2010; 62: Data on file: HCN Update on COPD and Asthma Diagnosis and Management Q Data from MedicalDirector General Practice Research Network (GPRN). 3 References: 1. Lung Foundation Australia. COPD: The statistics. lungfoundation.com.au. 2. Mapel D et al. Int Journal of COPD 2011: 6; Price D et al. Prim Care Respir J 2011; 20: Soriano JB et al. Lancet 2009; 374: Walters JA et al. Prim Care Respir J 2011; 20: Tinkelman DG et al. J Asthma 2006; 43: Jones RC et al. Respir Res 2008; 9: COPD why is the correct diagnosis important? COPD why is the correct diagnosis important? 40% of patients in general practice with a label of COPD have never had spirometry, and of these, 41% don t actually have the COPD 16% of non-respiratory admissions to hospital have undiagnosed COPD Of all acute exacerbations of COPD admitted to hospital, 34% represent a new or first diagnosis In reality, less than 5% of all patients in general practice have had spirometry Of admissions to hospital with an exacerbation of COPD as the discharge diagnosis: - 15% had normal spirometry, - 12% couldn t perform spirometry correctly - 21% didn t have spirometry, - only 56% had COPD Do patients hospitalized with COPD have airflow obstruction? Wu et al. Chest 2017:
2 FEV 1 (% of value at age 25 years) 06/11/2017 WHY USE SPIROMETRY? SPIROMETRIC DIAGNOSIS OF COPD Diagnosis based on symptoms and history alone is likely to miss up to 50% of COPD cases 1 Spirometry is the gold standard for evaluating airflow limitation 3 COPD IS DEFINED AS: Airflow obstruction that doesn t reverse to normal COPD usually has some degree of reversibility *As classified by Australian COPD-X guidelines References: 1. Walters J et al. Respir Med 2008; 102: Johns DP et al. Spirometer users and buyers guide Yang I et al, on behalf of Lung Foundation Australia. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease. Version 2.44, December Reference: 1. Yang I et al, on behalf of Lung Foundation Australia. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease. Version 2.44, December IDENTIFYING AT-RISK PATIENTS SCREENING SYMPTOM CHECKLIST Identify at-risk individuals for further testing and clinical diagnosis Time-course of FEV 1 decline in COPD COPD should be considered in any patient aged 35 years and over who meets one or more of the following criteria: 1 Smoker or ex-smoker Occupational exposure to dust, gas or fumes Cough Short of breath Experiences chest tightness or wheeze Smoked regularly and susceptible to the effects Onset of symptoms Never smoked or not susceptible to smoke Stopped smoking at age 45 years Has frequent chest infections At least once in every adult patient, even in the absence of symptoms 25 Severe disability Stopped smoking at age 65 years Reference: 1. Lung Foundation Australia. Position paper on the use of COPD screening devices for targeted COPD case finding in community settings Death Age (years) Adapted from Fletcher C and Peto R. BMJ1977;1: COPD WHAT INITIAL TREATMENT? Pharmacologic interventions Goal is symptom relief via bronchodilation Inhaled short-acting bronchodilators, as monotherapy or in combination, are first option for treatment of mild COPD 1-3 A STEPWISE APPROACH IS RECOMMENDED 1 MILD FEV % predicted few symptoms breathless on moderate exertion recurrent chest infections little or no effect on daily activities MODERATE FEV % predicted increasing dyspnoea breathless walking on level ground increasing limitation of daily activities cough and sputum production exacerbations requiring oral corticosteroids and/or antibiotics SEVERE FEV 1 <40% predicted dyspnoea on minimal exertion daily activities severely curtailed experiencing regular sputum production chronic cough exacerbations of increasing frequency and severity SAMAs Short-acting muscarinic receptor antagonists SABAs Short-acting ß 2 -adrenoreceptor agonists CHECK DEVICE USAGE TECHNIQUE AND ADHERENCE AT EACH VISIT Short-acting reliever medication: Short-acting ß 2-agonist (SABA) or short-acting muscarinic antagonist (SAMA) Symptom relief (some agents have been LAMA AND/OR LABA OR LAMA/LABA shown to also prevent exacerbations) Exacerbation prevention When FEV 1 <50% predicted AND LABA/ICS 2 exacerbations in 12 months References: 1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD Yang I et al, on behalf of Lung Foundation Australia. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease. Version 2.44, December Lung Foundation Australia. Stepwise management of stable COPD. February Reference: 1. Lung Foundation Australia. Stepwise management of stable COPD. February
3 COPD WHAT MAINTENANCE TREATMENT? Pharmacologic interventions Goal is sustained bronchodilation Inhaled long-acting bronchodilators, as monotherapy or in combination, are the cornerstone of maintenance treatment for all stages of COPD 1-3 ICS Use in COPD Not currently indicated as monotherapy There is now a global drive to reduce (inappropriate) use of ICS in COPD LAMAs Long-acting muscarinic receptor antagonists LABAs Long-acting ß 2 -adrenoreceptor agonists Several studies, including the WISDOM and INSTEAD randomised controlled trials, have demonstrated that it is possible to withdraw ICS without a corresponding increase in exacerbation frequency References: 1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD Yang I et al, on behalf of Lung Foundation Australia. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease. Version 2.44, December Lung Foundation Australia. Stepwise management of stable COPD. February ICS withdrawal is now recognised by the GOLD strategy as an appropriate treatment approach in selected patients Reference: 1. Data on file: HCN Update on COPD and Asthma Diagnosis and Management Q Data from MedicalDirector General Practice Research Network (GPRN). 14 ICS Use in COPD who not to withdraw GUIDELINES ARE NOT IMPLEMENTED CONSISTENTLY: AUSTRALIAN PRESCRIBING DATA A subgroup with an elevated peripheral eosinophil count may respond to ICS and may be at a greater risk of exacerbation if not on ICS (the optimal cut-off to define this subgroup is unclear) ICS are an option for those with 2 or more exacerbations in the last year Approximately 70% of COPD patients treated with a maintenance therapy are prescribed a LABA/ICS 1 A stratified, longitudinal cohort providing de-identified general practice data from a nationally representative cohort of over 400 Australian GPs. This database provides insight into clinical activity in Australia. GPs have identified patients as having a diagnosis of COPD. Reference: 1. Data on file: HCN Update on COPD and Asthma Diagnosis and Management Q Data from MedicalDirector General Practice Research Network (GPRN). 15 Reference: 1. Data on file: HCN Update on COPD and Asthma Diagnosis and Management Q Data from MedicalDirector General Practice Research Network (GPRN). 16 Other options in COPD Inhaled Corticosteroids in the Australian Market Mucolytics May reduce the likelihood of hospitalisation when given in high doses and may reduce exacerbations Oxygen Only if hypoxia is present (SaO 2 < 90%) when stable. No evidence to support O 2 in exercise induced desaturation below 90% if not hypoxic at rest Macrolides Reduce the rate of COPD exacerbations in some patients and the proportion of patients who experience an exacerbation (uncertainty about adverse effects of chronic therapy and patient selection) 17. 3
4 NEW OPTIONS FOR BRONCHODILATION IN COPD Potential LAMA / LABA / ICS combinations for COPD Available LAMA/LABA therapies Trade names of potential LAMA / LABA / ICS combinations (PBS listed at August 2014) Inhalers per patient* Dosing frequency Seebri Breezhaler / Symbicort Rapihaler (or Turbuhaler ) + or types 101,105,107 Once daily 107 / twice daily 101,105 Seebri Breezhaler / Seretide Accuhaler (or MDI) + or types 102,107 Once daily 107 / twice daily 102 Spiriva / Symbicort Rapihaler (or Turbuhaler ) Once daily 100 / types 100,101,105 + or twice daily 101,105 Ultibro Breezhaler (indacaterol/glycopyrronium) Brimica Genuair (eformoterol/aclidinium) Anoro Ellipta (vilanterol/umeclidinium) Spiolto Respimat (tiotropium/olodaterol) Spiriva / Seretide Accuhaler (or MDI) + or types 100,102 Once daily 100 / twice daily 102 Ultibro, Breezhaler are registered trademarks of Novartis Pharmaceuticals AG. Anoro, Ellipta are registered trademarks of the GlaxoSmithKline group of companies. Brimica, Genuair are registered trademarks of Almirall, S.A. References: 1. Price D et al. Prim Care Respir J 2013; 22: Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD Yang IA et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD Lung Foundation Australia. Stepwise management of stable COPD. February Bretaris Genuair / Symbicort Rapihaler (or Turbuhaler ) Bretaris Genuair / Seretide Accuhaler (or MDI) types63,101,105 + or Both twice daily63,101,105 + or Both twice daily 63,102 types 63,102 Stepwise management of stable COPD 1 The complete COPDX guidelines are available from the Lung Foundation of Australia at ROLE OF NON-PHARMACOLOGIC INTERVENTIONS Early implementation of non-pharmacologic interventions can slow COPD progression and improve quality of life 1 STOP Smoking cessation Vaccination Pulmonary rehabilitation Adapted from: 1. Lung Foundation. Stepwise Management of Stable COPD. February Stepwise Management of Stable COPD. Reproduced with permission from the publisher, Lung Foundation. Australia. Reference: 1. Yang I et al, on behalf of Lung Foundation Australia. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease. Version 2.44, December WHAT IS PULMONARYREHABILITATION? Pulmonary rehabilitation is a comprehensive, multidisciplinary program encompassing exercise training, education and support 1 WHAT ARE THE BENEFITS OF PULMONARY REHABILITATION IN COPD? Benefits reported from pulmonary rehabilitation include: 1,2 Exercise training (key component) Psychosocial support Education & behavioural interventions Components of pulmonary rehabilitation 2-4 Breathing techniques Nutritional interventions Reduced HOSPITAL ADMISSIONS NNT = 4* Reduced DEPRESSION AND ANXIETY Reduced MORTALITY NNT = 6* The minimum length of an effective rehabilitation program is 6 weeks If exercise training is maintained at home, health status remains above pre-rehabilitation levels 3 23 References: 1. Spruit M, et al. Am J Respir Crit Care Med 2013; 188, e Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD Frith P. A manual for pulmonary rehabilitation in Australia, Yang I et al, on behalf of Lung Foundation Australia. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease. Version 2.44, December *Based on Cochrane reviews of pulmonary rehabilitation for COPD. MCID, minimum clinically important difference. NNT, number needed to treat. References: 1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD Puhan MA et al. Cochrane Database Syst Rev 2011; (10):CD Global Initiative for Chronic Obstructive Lung Disease (GOLD). Pocket guide to COPD diagnosis, management and prevention
5 Percent Mortality 06/11/2017 IMMUNISATION REDUCES THE RISKS ASSOCIATED WITH INFLUENZA & PNEUMOCOCCAL INFECTION Definition of a COPD exacerbation Pneumococcal vaccine (13vconjugate) is recommended for those with: Moderate severe COPD who have never received pneumococcal immunisation; a first dose of 13vconjugate is recommended at diagnosis followed by the 23vPPV at one month and an additional doses pf 23vPPV at 5 years. For older adults who have already received an aged-based first dose of 23vPPV at aged 65 years (nonindigenous) or 50 years (indigenous), a single revaccination dose of 13vconjugate is recommended a minimum of 12 months after the previous dose An exacerbation of COPD is an acute event characterised by a worsening of the patient s respiratory symptoms that is beyond normal day-today variations (and leads to a change in medication) 1 For MILD COPD only use the 23vPPV only References: 1. Abramson M et al. COPD-X concise guide for primary care. Brisbane. Lung Foundation Australia. Version 3.02, August Yang I et al, on behalf of Lung Foundation Australia. The COPD- X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease. Version 2.44, December GOLD 2015 Recognition and treatment of exacerbations is critical - immediate and long-lasting consequences 3 8 Diagnosis of COPD exacerbation 12 Identify exacerbation and cause Physical examination Complementary tests (spirometry, VBG/ABG, oximetry, chest X-ray, ECG) Contribute to long-term decline in lung function 3 Reduce physical activity 4 Have a profound effect on quality of life 5 Often require hospital admission for treatment of respiratory failure 6 Associated with an increased risk of death, particularly if hospital admission is required 7 Have high socioeconomic costs, largely due to hospitalisation 8 3. Donaldson GC et al. Thorax Donaldson GC et al. Am J Respir Crit Care Med Wilkinson TM et al. Am J Respir Crit Care Med COPDX Guidelines Soler-Cataluna JJ et al. Thorax Blasi F et al. PLoS One 2014 Be certain of the COPD diagnosis Document increased respiratory symptoms Clinical suspicion COPD exacerbation Assess severity Differential diagnosis (chest X-ray, ECG) Pneumonia Pulmonary embolism Heart failure Arrhythmia Physical deconditioning Pneumothorax Pleural effusion Ischaemic heart disease Adapted from Soler-Cataluña JJ et al. Emergencias Soler-Cataluña JJ et al. Emergencias 2013 Exacerbations are associated with increased pulmonary and systemic inflammation 2 Bacteria Systemic inflammation Cardiovascular comorbidity TRIGGERS EFFECTS Viruses Exacerbation symptoms Inflamed COPD airways Greater airway inflammation Pollutants Bronchoconstriction oedema, mucus Expiratory flow limitation Dynamic hyperinflation Adapted from Wedzicha JA, Seemungal TA. Lancet Mortality following ED Visit for COPD exacerbation 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% 5% 9% 11% 16% 23% 32% 39% 30 Days 60 Days 90 Days 180 Days 1 Year 2 Years 3 Years Time Following Admission 2. Wedzicha JA, Seemungal TA. Lancet
6 Survival probability 06/11/2017 Kaplan-Meier survival function for the cohort of 73,106 patients from the time of their first ever hospitalisation for a COPD exacerbation over the 17- year follow-up period. COPD exacerbation 1 Inpatient mortality is 3.8% 12 month mortality is 23% Acute event mortality Myocardial infarction (MI) 2,3 Inpatient mortality less than 3% for NSTEMI and STEMI 5 year mortality is 15% 1. COPD-X Plan. X: Manage exacerbations Australian Institute of Health and Welfare Cardiovascular series no. 31. Cat. no.47. Canberra: AIHW. 3. AIHW. d= Increased exacerbations have been associated with COPD mortality risk 21 Severe acute exacerbations of COPD were found to have an independent negative impact on patient prognosis with greatest mortality risk for those patients with three or more acute COPD exacerbations (HR 4.13, 95% CI 1.80 to 9.41) Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD 21 Group A: no exacerbations Group B: 1 2 exacerbations requiring hospital management Group C: 3 exacerbations Time (months) A p< B p=0.069 Adapted from Soler-Cataluña et al :Data from from prospective study in a cohort of 304 male patients with stable COPD recruited in 1998 and followed for five years to investigate whether severe acute exacerbations of COPD (those requiring hospital management) exert a direct and independent effect on the survival of COPD patients C p< Optimising treatment for acute exacerbation of COPD 6 Bronchodilators Corticosteroids Antibiotics Controlled oxygen therapy Ventilatory assistance Signs and symptoms Airflow limitation Excess sputum production Airway inflammation Infection Hypoxia Hypercapnia Acidosis 33 CI=confidence interval; COPD = chronic obstructive pulmonary disease; HR=hazard ratio Reference. 21. Soler-Cataluña JJ et al. Thorax 2005;60: COPDX Guidelines 2014 Systemic corticosteroids reduce the severity of and shorten recovery from exacerbations 15 Controlled oxygen delivery is indicated only for hypoxia Oral corticosteroids are recommended for ease of administration 15 Administer oxygen via nasal cannula, aiming for SaO 2 of 88 92% Understand the poor relationship between SOB and hypoxaemia Prescribe oral corticosteroids (prednisolone mg or equivalent, taken in the morning) for 5-7 days and then stop; tapering the dose is confusing and rarely necessary 15 Avoid use of high-flow oxygen 15 May lead to hypoventilation and acute respiratory failure COPDX Concise Guide for Primary Care COPDX Concise Guide for Primary Care
7 Comprehensive follow up is required following discharge from hospital 15 Individualised discharge plans may reduce hospital length of stay and readmission rates 15 Pharmacological interventions following an exacerbation The aim of pharmacological treatment may be to treat symptoms (i.e. breathlessness) or to prevent deterioration (either by decreasing exacerbations or by reducing decline in QOL) or both A stepwise approach is recommended, irrespective of disease severity, until adequate control has been achieved Mild Moderate Severe CHECK DEVICE USAGE TECHNIQUE AND ADHERENCE AT EACH VISIT - Up to 90% of patients don t use devices correctly SHORT-ACTING RELIEVER MEDICATION: salbutamol or terbutaline or ipratropium bromide Hospital discharge plans should be shared with the primary care team, preferably within 24 hours of discharge 15 Discharged patients should be reviewed by a member of the primary care team within 7 days of discharge 15 Patients with chronic cough/ongoing sputum production should be monitored closely and taught airway clearance techniques 15 SYMPTOM RELIEF: Long acting antimuscarinic (tiotropium or glycopyrronium bromide) and/or long acting beta 2agonists (salmeterol, eformoterol or indacaterol # ). This may also help to prevent exacerbations. Once a long acting antimuscarinic is commenced, ipratropium bromide should be discontinued. EXACERBATION PREVENTION: (When FEV 1 < 50% predicted AND patient has had 2 or more exacerbations in the previous 12 months) inhaled glucocorticoids combined with long acting beta 2agonist (fluticasone/salmeterol or budesonide/eformoterol). LABA monotherapy (eformoterol, salmeterol or indacaterol) should be ceased once combination therapy (ICS/LABA) is initiated. 15. COPDX Concise Guide for Primary Care 2014 Adapted from Lung Foundation Australia : #Indacaterol should not be used in asthma or mixed airways disease. A differential diagnosis should be made to exclude asthma or mixed airways disease before initiating indacaterol; FEV 1=forced expiratory volume in one second; ICS=inhaled corticosteroids; LABA=long acting beta 2agonist 38 References: 36. Lung Foundation Australia. Stepwise Management of Stable COPD. Lung Foundation Australia. February 2014 Assessing device technique Inhaled Corticosteroids in the Australian Market Whenever possible, assess then re-assess device technique, and document prominently in you records Incorrect inhaler technique is astonishingly common (up to 94% of patients with COPD). No device is immune to this problem Poor inhaler technique is not surprising, as few doctors know how to use puffers correctly themselves Teaching correct technique can takes on average 2 minutes of your time Device choices: consider patient ability more than patient preference and aim for one type of device if using multiple drugs / puffers 15. MDI COPDX = metered Concise dose Guide inhalers for Primary Care UP TO 94% OF ASTHMA AND COPD PATIENTS INCORRECTLY USE THEIR INHALER DEVICE 1,2 Correct inhaler technique is essential Adherence and inhaler technique should be assessed at every visit 3 1 Patient demonstrates inhaler technique 2 Demonstrate correct technique highlighting steps that need correction Refer to Notebook for common errors of inhaler device use 3 Patient re-demonstrates inhaler technique repeat until all steps performed correctly Patient s adherence to COPD management strategy can be affected by: Skill and physical ability with inhaler technique Use of multiple inhalers Videos of correct inhaler technique for a range of devices can be found on: The National Asthma Council website: The Lung Foundation website: 41 References: 1. Lavorini F et al. Respir Med 2008; 102: Melani AS et al. Respir Med 2011; 105: National Asthma Council. Australian Asthma Handbook. Version 1.1. April
8 Learning outcomes Thank you Current issues in management of COPD Identification of COPD Initiation of treatment COPD exacerbations Non-pharmacological interventions Device selection IMMUNISATION REDUCES THE RISKS ASSOCIATED WITH INFLUENZA & PNEUMOCOCCAL INFECTION IMMUNISATION REDUCES THE RISKS ASSOCIATED WITH INFLUENZA & PNEUMOCOCCAL INFECTION Annual influenza immunisation 1,2 WHO WHEN All patients with COPD Immunise in early autumn A second immunisation in winter will increase antibody levels Regular pneumococcal immunisation 1,2 Pneumococcal polysaccharide vaccine: 23-valent (23vPPV; Pneumovax 23); 13-valent (Prevenar 13 ) WHAT WHO WHEN All patients with COPD Refer to COPD-X Concise Guide for schedule Booster after age 65 Annual influenza immunisation recommended 1,2 Influenza immunisation reduces the risk of exacerbations, hospitalisation and death in patients with COPD All patients with COPD should receive influenza vaccine immunisation Immunise in early autumn; a second immunisation in winter increases antibody levels Regular pneumococcal immunisation recommended, with a booster after age 65 1,2 Pneumococcal polysaccharide vaccine, 23-valent (23vPPV; Pneumovax 23) is highly effective in preventing invasive bacteraemic pneumococcal pneumonia in immunocompetent adults, although there is no direct evidence of its efficacy in preventing pneumococcal exacerbations of COPD References: 1. Abramson M et al. COPD-X concise guide for primary care. Brisbane. Lung Foundation Australia. Version 3.02, August Yang I et al, on behalf of Lung Foundation Australia. The COPD- X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease. Version 2.44, December References: 1. Abramson M et al. COPD-X concise guide for primary care. Brisbane. Lung Foundation Australia. Version 3.02, August Yang I et al, on behalf of Lung Foundation Australia. The COPD- X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease. Version 2.44, December
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationA multitude of devices
A multitude of devices Dr Andrew Scroop Respiratory Consultants 15 th September 2018 STEPWISE PHARMACOLOGICAL MANAGEMENT OF STABLE COPD COPD Inhalers MILD FEV 1 60 80% predicted few symptoms breathless
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationSABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
More informationCOPD in primary care: reminder and update
COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice
More information2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017
2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationAddress Comorbidities
Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationCOPD Device Workshop. Summary. Role of inhaler device in COPD. Why use inhaler device in COPD?
Part 1 Role of inhaler device in COPD COPD Device Workshop Dr Philip Lee Respiratory and Sleep Physician St George Hospital, Sydney Part 2 Part 3 Part 4 Incorrect inhaler technique-adverse clinical outcomes
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationCo. Durham & Darlington Respiratory Network COPD Treatment Guide
Co. Durham & Darlington Respiratory Network COPD Treatment Guide Age > 35, Productive cough, Breathless, Smoking Hx Spirometry (post-bronchodilator) COPD Advice Intensive smoking cessation support Vaccination
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationCOPD-X. Concise Guide for Primary Care
www.copdx.org.au This Guide aims to provide evidence-based practical recommendations for healthcare professionals on the diagnosis and management of chronic obstructive pulmonary disease (COPD). COPD-X
More informationCHARM Guidelines for the diagnosis and
\ CHARM Guidelines for the diagnosis and management of COPD City and Hackney CCG Homerton University Hospital NHS Foundation Trust Written by: Miss Hetal Dhruve, Specialist Pharmacist Respiratory Medicine,
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationRespiratory Health. Asthma and COPD
Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationWhy should I read this booklet?
COPD The basics Why should I read this booklet? This booklet contains information for people who have recently been told by their doctor that they have a condition called Chronic Obstructive Pulmonary
More informationCOPD Therapeutic Update
COPD Therapeutic Update The first ever NT patient.. Hubertus PA Jersmann MBBS, MD, PhD, FRACP, FThorSoc, AMA(M) Professor, School of Medicine, University of Adelaide Respiratory and Sleep Physician, Royal
More informationCOPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust
COPD GOLD Guidelines & Barnet inhaler choices Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationBetter Living with Obstructive Pulmonary Disease A Patient Guide
Better Living with Obstructive Pulmonary Disease A Patient Guide Second Edition November 2012 Queensland Health a Better Living with Chronic Obstructive Pulmonary Disease A Patient Guide is a joint project
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationINHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop
INHALERS for COPD Dr Christopher Worsnop Department of Respiratory Medicine Austin Hospital INTRODUCTION Most drugs for COPD are given via inhalers. This reduces the dose that needs to be given and delivers
More informationCOPD Prescribing Guidelines
Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning
More informationCommunity COPD Service Protocol
Community COPD Service Protocol Acknowledgements This protocol is based on the following documents: 1. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationChronic Obstructive Pulmonary Disease (COPD) Clinical Guideline
Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationDr Stephen Child. General Physician Auckland. 14:20-14:40 Secondary Care Perspective
Dr Stephen Child General Physician Auckland 14:20-14:40 Secondary Care Perspective Wheeze Witchery Stephen Child MD, FRACP, FRCPC General Physician Respiratory Interest Director of Clinical Training Auckland
More informationAdjunct Associate Professor Robert Young
Adjunct Associate Professor Robert Young General Physician Auckland City Hospital 7:00-7:55 GlaxoSmithKline Breakfast Session - COPD New approaches in the management of COPD Dr Robert Young BMedSc MBChB
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationTo describe the impact of COPD exacerbations and the importance of the frequent exacerbator phenotype.
Educational aims To describe the impact of COPD exacerbations and the importance of the frequent exacerbator phenotype. To describe the spectrum of pharmacological and non-pharmacological interventions
More informationMedicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD) Approved by Prof. Michael Barry, Clinical Lead, MMP. Date approved Version 1 July 2014 Date updated Version
More informationExacerbations of COPD. Dr J Cullen
Exacerbations of COPD Dr J Cullen Definition An AECOPD is a sustained worsening of the patient s clinical condition from their stable state that is beyond their usual day-to-day variation is acute in onset
More informationCOPD/Asthma. Prudence Twigg, AGNP
COPD/Asthma Prudence Twigg, AGNP COPD/Asthma Qualifying Diagnosis Known diagnosis of COPD/asthma or CXR showing COPD with hyperinflated lungs and no infiltrates + two or more: Wheezing, SOB, increased
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationPresented by UIC College of Nursing
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long-acting inhalers and emergency use inhalers.
More informationChronic Obstructive Pulmonary Disease 1/18/2018
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long acting inhalers and emergency use inhalers.
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationCurriculum Vitae. Head of Public Wing HCU - RSCM. Head of ICU Sari Asih Ciledug Hospital
Curriculum Vitae Name : Dr. Ceva W. Pitoyo,SpPD,K-P,KIC,FINASIM POB / DOB : Jakarta, March 8th 1968 Education : o General Practitioner : FKUI 1993 o Internist : FKUI 2002 o Pulmonology Consultant : PAPDI-UI
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationCOPD. Helen Suen & Lexi Smith
COPD Helen Suen & Lexi Smith What is COPD? Chronic obstructive pulmonary disease: a non reversible, long term lung disease Characterized by progressively limited airflow and an inability to perform full
More informationFact. Objectives 1/6/2016. Reducing Hospital Readmissions for Chronic Obstructive Pulmonary Disease (COPD)
Reducing Hospital Readmissions for Chronic Obstructive Pulmonary Disease (COPD) Jin S. Oh, PharmD Larkin Community Hospital January 10, 2016 Fact COPD is the third leading cause of death in the United
More informationResearch Review. Salmeterol/fluticasone propionate (Seretide ) in COPD. Extended listing for salmeterol/fluticasone propionate in COPD
Research Review Salmeterol/fluticasone propionate (Seretide ) in COPD Extended listing for salmeterol/fluticasone propionate in COPD In New Zealand, salmeterol/fluticasone propionate (SFC) (Seretide )
More informationADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma.
ADULT ASTHMA GUIDE SUMMARY This summary provides busy health professionals with key guidance for assessing and treating adult asthma. Its source document Asthma and Respiratory Foundation NZ Adult Asthma
More informationWhat is New in COPD: Times Are Changing! Meredith Chiasson, MD, FRCPC April 6, 2018
What is New in COPD: Times Are Changing! Meredith Chiasson, MD, FRCPC April 6, 2018 No disclosures Disclosures objectives How to diagnose & Assess severity Treatment: Pharmacologic Non-Pharmacologic Maintenance
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationCOPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre
COPD The New Epidemic Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre Conflict Disclosure Information Speaker: Dr. Peter Lin Title of Talk: COPD The New Epidemic Financial
More informationChronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD) Definition of COPD Airflow obstruction that is: o Not fully reversible o Progressive o Does not change markedly over several months Combination of airway and
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationCommissioning for Better Outcomes in COPD
Commissioning for Better Outcomes in COPD Dr Matt Kearney Primary Care & Public Health Advisor Respiratory Programme, Department of Health General Practitioner, Runcorn November 2011 What are the Commissioning
More informationOPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures
OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING J. Michael Fuller, MD, MEd, FACP, FCCP Associate Professor of Medicine University of South Carolina Greenville DISCLOSURES I have no financial or other
More informationThis is the publisher s version. This version is defined in the NISO recommended practice RP
Journal Article Version This is the publisher s version. This version is defined in the NISO recommended practice RP-8-2008 http://www.niso.org/publications/rp/ Suggested Reference Chong, J., Karner, C.,
More informationDr Michael Ho AGENDA. Asthma control requires treating underlying pathophysiology. The goal of asthma management To achieve overall asthma control
Dr Michael Ho Consultant Respiratory & Sleep Physician Dandenong Respiratory Group Director of South Eastern Private Sleep Centre Part 1 AGENDA Generalised asthma management: Stepwise approach Part 2 Inhaler
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationChronic Obstructive Pulmonary Disease: What s New in Therapeutic Management?
Chronic Obstructive Pulmonary Disease: What s New in Therapeutic Management? Sabrina Sherwood, PharmD PGY2 Internal Medicine Resident University of Utah Health September 29, 2018 Disclosures Relevant disclosures
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease Catherine Whittaker (BPharm, MRPharmS) Abstract Chronic Obstructive Pulmonary Disease affects millions of people, has a major impact on quality of life and has become
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationNational COPD Audit Programme
National COPD Audit Programme Planning for every breath National Chronic Obstructive Pulmonary Disease (COPD) Audit Programme: Primary care audit () 2015 17 Data analysis and methodology Section 4: Providing
More informationChronic Obstructive Pulmonary Disease
Page 1 of 5 Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease (COPD) is an 'umbrella' term for people with chronic bronchitis, emphysema, or both. With COPD the airflow to the
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationTreatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1
58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family
More informationDesign - Multicentre prospective cohort study. Setting UK Community Pharmacies within one CCG area within the UK
Enabling Patient Health Improvements through COPD (EPIC) Medicines Optimisation within Community Pharmacy: a prospective cohort study Abstract Objectives To improve patients ability to manage their own
More informationCOPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS
COPD: GOLD guidelines 2017 Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationDr Stephen Child. Chief Medical Officer Southern Cross Health Society Auckland
Dr Stephen Child Chief Medical Officer Southern Cross Health Society Auckland 7:00-7:55 GlaxoSmithKline Breakfast Session - Hot Topics in Airways Disease: COPD and Asthma Hot Topics in Airways Disease:
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationinformation Chronic Obstructive Pulmonary Disease - COPD (1 of 5) What is COPD? What is going on in my lungs? What are the symptoms of COPD?
information If you need this information in another language or medium (audio, large print, etc) please contact the Patient Advice and Liaison Service (PALS) on 0800 374 208 email: pal.service@ salisbury.nhs.uk.
More informationCOPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes
COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationPotential risks of ICS use
Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary and secondary
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More informationPFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA
PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation
More informationEvidence Review for Prescribing Clinical Network
Summary page Evidence Review for Prescribing Clinical Network Treatment: LABA/LAMA Combination devices in COPD Anoro Ellipta, Ultibro and Duaklir Genuair Prepared by: Noreen Devanney Topic Submitted by:
More information